SCYNEXIS (SCYX) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
27 Apr, 2026Executive summary
A special meeting is scheduled for May 19, 2026, to vote on a reverse stock split and reduction of authorized shares.
The reverse stock split ratio will be between 1-for-5 and 1-for-10, at the Board's discretion.
The proposal aims to help maintain compliance with Nasdaq's minimum bid price requirement and avoid delisting.
The Board recommends voting in favor of the proposal.
Voting matters and shareholder proposals
Only one proposal is up for vote: amending the Certificate of Incorporation to effect a reverse stock split and reduce authorized shares.
The Board has discretion to determine the exact split ratio and timing.
Approval requires a majority of votes cast; abstentions and broker non-votes have no effect.
The proposal is considered a routine matter, so brokers may vote uninstructed shares.
No other matters are expected at the meeting.
Board of directors and corporate governance
The Board retains authority to implement or abandon the reverse stock split after shareholder approval.
Board discretion allows flexibility to respond to market conditions and Nasdaq requirements.
Latest events from SCYNEXIS
- Resale registration for 87M shares from a private placement; proceeds only from warrant exercises.SCYX
Registration filing1 May 2026 - Key votes include board elections, auditor ratification, and major share authorization changes.SCYX
Proxy filing1 May 2026 - Annual meeting seeks approval for director elections, equity plan expansion, and capital increase.SCYX
Proxy filing30 Apr 2026 - Shareholders will vote on director elections, compensation, equity plan, and capital structure changes.SCYX
Proxy filing20 Apr 2026 - Shareholders will vote on a reverse stock split to help maintain Nasdaq listing compliance.SCYX
Proxy filing17 Apr 2026 - Acquisition of SCY-770 for ADPKD offers major commercial potential and no royalty obligations.SCYX
M&A announcement2 Apr 2026 - SCY-247 advances as a potent antifungal with strong clinical data and significant market potential.SCYX
investor presentation4 Mar 2026 - 2025 revenue rose sharply on GSK deals; SCY-247 clinical progress and cash runway extended.SCYX
Q4 20254 Mar 2026 - Advancing next-gen antifungal SCY-247 and expanding GSK partnership, with strong financials.SCYX
H.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026